Vivo Capital LLC Lowers Stock Holdings in Dyne Therapeutics, Inc. $DYN

Vivo Capital LLC cut its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 40.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,557,466 shares of the company’s stock after selling 1,057,494 shares during the period. Dyne Therapeutics makes up 2.3% of Vivo Capital LLC’s investment portfolio, making the stock its 13th biggest holding. Vivo Capital LLC’s holdings in Dyne Therapeutics were worth $28,237,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Creative Planning raised its stake in shares of Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics in the 1st quarter valued at $26,000. Caxton Associates LLP increased its stake in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its stake in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $25.73 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of -7.73 and a beta of 1.06. The company has a 50 day moving average price of $21.08 and a 200 day moving average price of $18.82. Dyne Therapeutics, Inc. has a one year low of $9.57 and a one year high of $26.26.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.34). Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.01 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on DYN shares. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada lifted their price target on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, TD Cowen began coverage on Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $34.58.

Insider Buying and Selling

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares of the company’s stock, valued at $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian S. Posner purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were purchased at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the purchase, the director directly owned 24,500 shares in the company, valued at $415,030. This trade represents a 8.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. 9.46% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.